2023. Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus. SKIN The Journal of Cutaneous Medicine. 7, 4 (Jul. 2023), s226. DOI:https://doi.org/10.25251/skin.7.supp.226.